Vertex Pharmaceuticals (NASDAQ:VRTX) Posts Earnings Results, Misses Estimates By $0.01 EPS

Vertex Pharmaceuticals (NASDAQ:VRTX) announced its earnings results on Monday. The pharmaceutical company reported $4.73 earnings per share for the quarter, missing the consensus estimate of $4.74 by ($0.01), FiscalAI reports. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The business had revenue of $3.33 billion for the quarter, compared to analysts’ expectations of $3.23 billion. During the same period in the previous year, the company earned $4.52 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 12.5% on a year-over-year basis.

Here are the key takeaways from Vertex Pharmaceuticals’ conference call:

• Positive Sentiment: Vertex reported second-quarter revenue of $3.3 billion, up 12% year over year, and raised 2026 revenue guidance to $13.1 billion–$13.2 billion. Management maintained its target of at least $500 million in non-CF revenue, while expecting operating expenses near the high end of its $5.65 billion–$5.75 billion range.
• Positive Sentiment: The cystic fibrosis franchise remained strong, with global revenue up 11% and ALYFTREK exceeding $1 billion in first-half revenue. Vertex highlighted rapid ALYFTREK adoption, including more than one-third of eligible patients in Germany and the U.K., and is pursuing additional approvals in younger children and rare mutations.
• Positive Sentiment: CASGEVY revenue rose to $76 million in the second quarter, up roughly 75% sequentially, while JOURNAVX revenue reached $50 million, up about 70% sequentially. CASGEVY patient initiations and infusions continued to build, and JOURNAVX prescriptions, prescriber adoption, hospital pathways, and payer coverage expanded significantly.
• Negative Sentiment: JOURNAVX’s rapid prescription growth is increasing use of Vertex’s patient support program because of remaining payer restrictions, delaying gross-to-net normalization until the first half of 2027. Management also cautioned that quarterly revenue may remain volatile as channel inventory and reimbursement patterns normalize.
• Positive Sentiment: Vertex is preparing for a potential November 30 FDA decision on povetacicept in IgA nephropathy, citing strong efficacy, monthly at-home auto-injector dosing, and a favorable safety profile. The company also advanced multiple pipeline programs, including completion of enrollment in studies of inaxaplin and VX-407, an upcoming type O islet-cell therapy trial, and the planned acquisition of Crinetics to establish a rare-endocrine franchise.

Vertex Pharmaceuticals Stock Down 1.3%

Shares of Vertex Pharmaceuticals stock opened at $470.72 on Tuesday. Vertex Pharmaceuticals has a 52-week low of $362.50 and a 52-week high of $533.67. The company has a 50 day moving average of $471.34 and a 200 day moving average of $460.44. The company has a market capitalization of $119.47 billion, a P/E ratio of 27.92, a P/E/G ratio of 2.15 and a beta of 0.30.

Analyst Upgrades and Downgrades

Several equities analysts have commented on VRTX shares. Sanford C. Bernstein decreased their price target on shares of Vertex Pharmaceuticals from $577.00 to $572.00 and set an “outperform” rating for the company in a research report on Tuesday, May 5th. Royal Bank Of Canada upped their price objective on Vertex Pharmaceuticals from $543.00 to $570.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Wall Street Zen cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, June 28th. Truist Financial lifted their target price on Vertex Pharmaceuticals from $542.00 to $560.00 and gave the company a “buy” rating in a report on Monday, July 13th. Finally, UBS Group boosted their target price on Vertex Pharmaceuticals from $545.00 to $585.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Twenty-two investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $559.61.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Duncan Mckechnie sold 1,541 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $519.00, for a total value of $799,779.00. Following the sale, the executive vice president directly owned 11,001 shares of the company’s stock, valued at approximately $5,709,519. This represents a 12.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 596 shares of the firm’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $482.50, for a total transaction of $287,570.00. Following the completion of the sale, the chief marketing officer owned 15,337 shares in the company, valued at $7,400,102.50. The trade was a 3.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 17,452 shares of company stock valued at $8,103,997. Insiders own 0.20% of the company’s stock.

Institutional Trading of Vertex Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Motiv8 Investments LLC acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth about $26,000. Swiss RE Ltd. acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth about $28,000. Kelleher Financial Advisors purchased a new stake in Vertex Pharmaceuticals during the third quarter worth approximately $39,000. Triumph Capital Management purchased a new stake in Vertex Pharmaceuticals during the third quarter worth approximately $43,000. Finally, Sfam LLC acquired a new position in Vertex Pharmaceuticals in the fourth quarter valued at approximately $45,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue rose 12.5% year over year to $3.33 billion, topping analysts’ $3.23 billion estimate. Growth was supported by strong demand for Vertex’s cystic fibrosis medicines, as well as continued contributions from sickle cell disease, beta thalassemia and acute pain products. Vertex raises annual revenue forecast on cystic fibrosis drugs strength
• Positive Sentiment: Vertex raised its 2026 revenue outlook to $13.1 billion-$13.2 billion, implying a $13.15 billion midpoint slightly above the $13.0 billion analyst consensus. The higher forecast reflects sustained cystic fibrosis sales momentum. Vertex Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; Lifts 2026 Guidance
• Positive Sentiment: The pending acquisition of Crinetics would expand Vertex into rare endocrine diseases through Paltusotine and create a fifth commercial pillar, potentially diversifying growth beyond cystic fibrosis. Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Adjusted EPS increased to $4.73 from $4.52 a year earlier and was essentially in line with the $4.74 consensus in some reports, while other estimates showed a slightly wider miss at $4.79. This modest earnings shortfall limited the positive reaction to the revenue beat. Vertex Pharmaceuticals Q2 2026 Earnings Call Transcript
• Negative Sentiment: Investors appear concerned about the approximately $10 billion Crinetics purchase, including its execution risk and the need to absorb a sizable acquisition while Vertex continues investing in its pipeline. Those concerns, combined with the EPS miss, contributed to the stock’s decline despite stronger sales guidance. Vertex Raises 2026 Guidance, But Shares Dip For One Key Reason

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.